The Gabrail Cancer Center has announced an exciting new clinical trial aimed at evaluating the combination of the T-cell engager elranatamab with Starton Therapeutics’ controlled low-dose lenalidomide (STAR-LLD). Led by Dr. Nashat Gabrail, this investigator-initiated study is set to explore critical aspects of treatment for patients with relapsed or refractory multiple myeloma.
Trial Overview
The clinical trial, which has received the green light from the U.S. Food and Drug Administration (FDA) under an Investigational New Drug (IND) application, will focus on assessing the dosing, safety, and preliminary effectiveness of STAR-LLD in conjunction with elranatamab. By combining these therapies, the study aims to enhance the durability and depth of patient responses while minimizing the hematologic toxicity typically associated with conventional immunomodulatory drugs (IMiDs).
Understanding T-cell Engagers
T-cell engagers, particularly bispecific antibodies targeting BCMA, have emerged as promising treatments for multiple myeloma and lymphoma. Unlike CAR-T cell therapies, which necessitate specialized facilities and intricate administration protocols, T-cell engagers can be administered in community oncology settings. This accessibility opens the door for broader patient populations to benefit from these innovative therapies.
Despite the positive response rates seen with T-cell engagers, many patients ultimately experience disease progression. Recent studies suggest that factors such as decreasing T-cell fitness and T-cell exhaustion may contribute to this acquired resistance. The integration of IMiDs presents a potential strategy to positively influence the tumor microenvironment, thereby improving patient outcomes. This trial aims to address these challenges directly.
Addressing Hematologic Toxicity
One of the significant hurdles in combining traditional oral lenalidomide with T-cell engagers is the increased risk of hematologic toxicity and infections. Such complications can lead to dose reductions, treatment interruptions, and even discontinuations, potentially diminishing the effectiveness of the therapy. Dr. Gabrail emphasizes the importance of overcoming these barriers to optimize treatment.
He notes, “The additive hematologic toxicity from combining immunomodulatory agents with T-cell engagers is a major concern. STAR-LLD’s controlled delivery system offers a unique opportunity to maintain or even enhance therapeutic efficacy while reducing the toxicity burden. This could extend the duration of patient responses to bispecific therapy, which is incredibly exciting.”
Innovative Approach to Delivery
The study will specifically investigate the controlled low-dose delivery of lenalidomide. This method is designed to provide sustained exposure to the drug, focusing on its immunomodulatory effects while avoiding the high peak concentrations associated with traditional oral dosing. By leveraging existing clinical and scientific insights into the combinations of IMiDs and CELMoDs with T-cell engagers, researchers hope to enhance the therapeutic profile of this new treatment approach.
Real-World Impact
Carrie Smith, RN and Chief Operations Officer of the Research Division at the Gabrail Cancer Center, highlights the significance of conducting this study in a community oncology setting. “Many multiple myeloma patients in the U.S. receive care in community practices rather than academic centers. It is crucial to generate safety and efficacy data that reflects real-world clinical practice, ensuring that our findings can be translated into everyday treatment scenarios.”
Looking Ahead
Enrollment for the trial is expected to commence in the fourth quarter of 2026, marking a significant step forward in the exploration of innovative treatment options for patients battling relapsed or refractory multiple myeloma.
Conclusion
The Gabrail Cancer Center’s initiative to study the combination of elranatamab and STAR-LLD represents a promising advancement in the field of oncology. By focusing on optimizing treatment efficacy while minimizing risks, this trial could pave the way for improved patient outcomes and greater accessibility to cutting-edge therapies. The commitment to conducting this research in a community setting underscores the importance of improving care for all patients facing this challenging diagnosis.
- Takeaways:
- The trial will assess the safety and efficacy of STAR-LLD with elranatamab in multiple myeloma.
- T-cell engagers offer a promising alternative to CAR-T therapies.
- The study aims to mitigate hematologic toxicity associated with traditional IMiDs.
- Community oncology settings play a crucial role in advancing treatment options.
- Enrollment is set to begin in late 2026, signaling a forward momentum in myeloma research.
Read more → www.jsonline.com